Pubblicazioni

Bone-Targeted Agents

2016 - Bone Metastases from Prostate Cancer

Santini, D; Ripamonti, C; Zoccoli, A; Iuliani, M; Fioramonti, M; Ribelli, G; Pantano, F

Bone-Targeted Agents

2016 - Bone Metastases from Prostate Cancer

Santini, D; Ripamonti, C; Zoccoli, A; Iuliani, M; Fioramonti, M; Ribelli, G; Pantano, F

RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw

2016 - JOURNAL OF THE NATIONAL CANCER INSTITUTE

Fusco, V; Campisi, G; Numico, G; Migliorati, Ca; Santini, D; Bedogni, A

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis

2016 - ONCOTARGET

Vincenzi, B; Nannini, M; Fumagalli, E; Bronte, G; Frezza, Am; De Lisi, D; Ceruso, Ms; Santini, D; Badalamenti, G; Pantaleo, Ma; Russo, A; Dei Tos, A; Casali, P; Tonini, G

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

2016 - ONCOTARGET

Gardini, Ac; Scarpi, E; Faloppi, L; Scartozzi, M; Silvestris, N; Santini, D; de Stefano, G; Marisi, G; Negri, Fv; Foschi, Fg; Valgiusti, M; Ercolani, G; Frassineti, Gl

Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma

2016 - CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cereda, S; Milella, M; Cordio, S; Leone, F; Aprile, G; Galiano, A; Mosconi, S; Vasile, E; Santini, D; Belli, C; Auriemma, A; Novarino, A; Vaccaro, V; Martines, C; Marino, D; Lutrino, Se; Palazzo, V; Reinach, B; Aldrighetti, L; Reni, M

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study

2016 - ONCOTARGET

Verzoni, E; De Giorgi, U; Derosa, L; Caffo, O; Boccardo, F; Facchini, G; Porcu, L; De Vincenzo, F; Zaniboni, A; Chiuri, Ve; Fratino, L; Santini, D; Adamo, V; De Vivo, R; Dinota, A; Messina, C; Ricotta, R; Caserta, C; Scavelli, C; Susi, M; Tartarone, A; Surace, G; Mosca, A; Bruno, M; Barni, S; Grassi, P; Procopio, G

Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR"

2016 - CANCER TREATMENT REVIEWS

Sartore-Bianchi, A; Siena, S; Tonini, G; Bardelli, A; Santini, D.

Adjuvant bisphosphonates in early breast cancer. Consensus guidance for clinical practice from a European Panel

2016 - ANNALS OF ONCOLOGY

Hadji, P; Coleman, Re; Wilson, C; Powles, Tj; Clezardin, P; Aapro, M; Costa, L; Body, Jj; Markopoulos, C; Santini, D; Diel, I; Di Leo, A; Cameron, D; Dodwell, D; Smith, I; Gnant, M; Gray, R; Harbeck, N; Thurlimann, B; Untch, M; Cortes, J; Martin, M; Albert, Us; Conte, Pf; Ejlertsen, B; Bergh, J; Kaufmann, M; Holen, I

Procalcitonin as diagnostic marker of infection in solid tumors patients with fever

2016 - SCIENTIFIC REPORTS

Vincenzi, B; Fioroni, I; Pantano, F; Angeletti, S; Dicuonzo, G; Zoccoli, A; Santini, D; Tonini, G

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016 - EXPERT OPINION ON DRUG SAFETY

Fusco, V; Santini, D; Armento, G; Tonini, G; Campisi, G.

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study

2016 - PLOS ONE

Gori, S; Inno, A; Rossi, V; Turazza, M; Fiorio, E; Fabi, A; Bisagni, G; Foglietta, J; Santini, D; Pavese, I; Pellegrino, A; Zambelli, A; Vici, P; Leonardi, V; Barni, S; Saracchini, S; Bogina, G; Marchetti, F; Duranti, S; Lunardi, G; Montemurro, F

Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3

2016 - EUROPEAN UROLOGY

Santoni, M; Scarpelli, M; Lopez-Beltran, A; Cheng, L; Briganti, A; Montorsi, F; Montironi, R; Santini, D

Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain

2016 - JOURNAL OF CLINICAL ONCOLOGY

Bandieri, E; Romero, M; Ripamonti, Ci; Artioli, F; Sichetti, D; Fanizza, C; Santini, D; Cavanna, ; Melotti, B; Conte, Pf; Roila, F; Cascinu, S; Bruera, E; Tognoni, G; Luppi, M

Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

2016 - SCIENTIFIC REPORTS

Santini, D; Barni, S; Intagliata, S; Falcone, A; FerraÃ¹, F; Galetta, D; Moscetti, L; La Verde, N; Ibrahim, T; Petrelli, F; Vasile, E; Ginocchi, L; Ottaviani, D; Longo, F; Ortega, C; Russo, A; Badalamenti, G; CollovÃ , E; Lanzetta, G; Mansueto, G; Adamo, V; De Marinis, F; Satolli, Ma; Cantile, F; Mancuso, A; Tanca, Fm; Addeo, R; Russano, M; Sterpi, M; Pantano, F; Vincenzi, B; Tonini, G

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

2016 - ONCOTARGET

Passiglia, F; Bronte, G; Bazan, V; Natoli, C; Rizzo, S; Galvano, A; Listi, A; Cicero, G; Rolfo, C; Santini, D; Russo, A

Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

2016 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Silvestris, N; Longo, V; Cellini, F; Reni, M; Bittoni, A; Cataldo, I; Partelli, S; Falconi, M; Scarpa, A; Brunetti, O; Lorusso, V; Santini, D; Morganti, A; Valentini, V; Cascinu,

Treatment of advanced renal-cell carcinoma

2016 - NEW ENGLAND JOURNAL OF MEDICINE

Santini, D; Tonini, G

The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

2016 - TARGETED ONCOLOGY

Puzzoni, M; Silvestris, N; Leone, F; Giampieri, R; Faloppi, L; Demurtas, L; Dell'Aquila, E; Marino, D; Brunetti, O; Garattini, Sk; Ongaro, E; Astara, G; Orgiano, L; Aprile, G; Santini, D; Scartozzi, M

Drug-induced hepatotoxicity in cancer patients - implication for treatment

2016 - EXPERT OPINION ON DRUG SAFETY

Vincenzi, B; Armento, G; Spalato Ceruso, M; Catania, G; Leakos, M; Santini, D; Minotti, G; Tonini, G

Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer

2016 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Maugeri-Sacca, M; Barba, M; Vici, P; Pizzuti, L; Sergi, D; Catenaro, T; Di Lauro, L; Mottolese, M; Santini, D; Milella, M; De Maria, R

Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials

2016 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Massari, F; Modena, A; Ciccarese, C; Pilotto, S; Maines, F; Bracarda, S; Sperduti, I; Giannarelli, D; Carlini, P; Santini, D; Tortora, G; Porta, C; Bria, E

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

2016 - FUTURE ONCOLOGY

Veccia, A; Caffo, O; De Giorgi, U; Di Lorenzo, G; Ortega, C; Scognamiglio, F; Aieta, M; Facchini, G; Mansueto, G; Mattioli, R; Procopio, G; Zagonel, V; D'Angelo, A; Spizzo, G; Bortolus, R; Donini, M; Lo Re, G; Massari, F; Vicario, G; Zucali, Pa; Alesini, D; Bonetti, A; Mucciarini, C; Nicodemo, M; Berruti, A; Fratino, L; Lodde, M; Messina, C; Perin, A; Santini, D; Sava, T; Tucci, M; Basso, U; Maines, F; Burgio, Ls; Galligioni, E

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy

2016 - SCIENTIFIC REPORTS

Faloppi, L; Del Prete, M; Gardini, Ac; Santini, D; Silvestris, N; Bianconi, M; Giampieri, R; Valgiusti, M; Brunetti, O; Bittoni, A; Andrikou, K; Lai, E; Dessi, A; Cascinu, S; Scartozzi, M

New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors

2016 - EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

Ciccarese, C; Alfieri, S; Santoni, M; Santini, D; Brunelli, M; Bergamini, C; Licitra, L; Montironi, R; Tortora, G; Massari, F